To further investigate the pattern of EGFR degradation in NSCLC cells, we treated GSDME-knockdown H157 cells with aloxistatin (E64D, a cell-permeable and irreversible broad-spectrum cysteine protease inhibitor) and MG132 (a proteasome inhibitor). Here, EGFR is linked to non-small cell lung carcinoma.